Novartis
February 4, 2019
[vc_row][vc_column][vc_column_text] Cell and gene therapies (CGTs) offer an unprecedented opportunity to treat diseases for which existing interventions are inadequate, potentially offering cures for previously terminal illnesses. […]
August 31, 2017
[vc_row][vc_column][vc_column_text] Gilead Sciences has ended its M&A moratorium with an $11.9B all-cash acquisition of CAR-T Cell Therapy pioneers Kite Pharma. Kite’s leading drug Axi-Cel is expected […]
November 29, 2016
[vc_row][vc_column][vc_column_text]The field of CAR-T immunotherapy presents a tantalising idea: reengineering a patient’s immune cells to attack cancer. CAR-T immunotherapy has the potential to revolutionise the way […]
February 21, 2016
For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that […]
September 10, 2015
On August 31, 2015 Google Life Sciences and French pharma giant Sanofi announced that the two companies will work together on new digital technology and tools […]